Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Nielsen, Stine NEriksson, Frank
Rosthoej, Susanne
Andersen, Mette K
Forestier, Erik
Hasle, Henrik
Hjalgrim, Lisa L
Aasberg, Ann
Abrahamsson, Jonas
Heyman, Mats
Jónsson, Ólafur G
Pruunsild, Kaie
Vaitkeviciené, Goda E
Vettenranta, Kim
Schmiegelow, Kjeld
Issue Date
2017-10
Metadata
Show full item recordCitation
Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers. 2017, 64 (10) Pediatr Blood CancerAbstract
The rate of second cancer was generally highest in patients with low-risk ALL, but we could not identify a subset at higher risk than others.Description
To access publisher's full text version of this article click on the hyperlink belowAdditional Links
http://onlinelibrary.wiley.com/doi/10.1002/pbc.26518/epdfRights
Archived with thanks to Pediatric blood & cancerae974a485f413a2113503eed53cd6c53
10.1002/pbc.26518
Scopus Count
Collections
Related articles
- Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
- Authors: Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R, Nordic Society for Paediatric Haematology and Oncology.
- Issue date: 2009 Jun 11
- Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
- Authors: Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K, Nordic Society of Paediatric Haematology, Oncology.
- Issue date: 2014 May
- Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
- Authors: Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K
- Issue date: 2015 Jan
- Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
- Authors: Schmiegelow K, Forestier E, Kristinsson J, Söderhäll S, Vettenranta K, Weinshilboum R, Wesenberg F, Nordic Society of Paediatric Haematology and Oncology.
- Issue date: 2009 Mar
- Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
- Authors: Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P, Dördelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe M, Schwab M
- Issue date: 2009 Aug 13